Lobe Sciences Ltd (LOBE)

Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common SharesJune 9, 2026 6:00 AM
ACCESS NewswireDirectors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholdersThe Canadian Securities Exchange has accepted the share issuance, allowing the Company to complete the settlementCompany remains well-positioned with C$4.96 million in cash and short-term investments as of its most recent quarter ended February 28, 2026Subsidiary R&D programs remain on track and on budget, with continued de-risking through Lobe's disciplined development model VANCOUVER, BC / ACCESS Newswire / June 9, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F), a clinical-stage biopharmaceutical company advancing high-potential drug candidates for diseases with significant unmet medical needs through a disciplined pharmaceutical development platform and focused subsidiary companies, today announced that its directors and officers have settled C$1,372,761.20 in accrued management and director fees through the issuance of 12,749,643 common shares of the Company (the "Settlement Shares") at a deemed price of C$0.11 per share (the "Debt Settlement").Management and the Board elected to receive equity in place of cash compensation to further align with shareholders. The Canadian Securities Exchange has accepted the issuance of the Settlement Shares. The shares will be subject to a four-month hold period from the date of issuance in accordance with applicable Canadian securities laws, in addition to any other restrictions that may apply under the securities laws of jurisdictions outside Canada.Lobe has continued to increase investment in its clinical development programs. Research and development expenditures reached C$2.12 million in the first half of fiscal 2026, compared to approximately C$20,000 in the prior-year period, reflecting the Company's transition from pre-clinical preparation to active clinical execution across its core programs. Following completion of the share settlement, management and directors' ownership of the Company exceeds 40%.Lobe's financial position remains strong, with C$4.96 million in cash and short-term investments including cash held in its subsidiaries, as of the end of its most recent quarter, per its financial statements, as filed on SEDAR+. The Company's subsidiary R&D programs remain on track and on budget, with continued progress intended to de-risk the assets through clinical, regulatory, and financing milestones. The L-130 therapeutic program is operated through Cynaptec Pharmaceuticals, Inc., a majority-owned subsidiary of Lobe. The S-100 sickle cell disease program is operated through Applied Lipid Technologies, Inc., a wholly owned subsidiary of Lobe.Lobe's subsidiary model is designed to finance clinical programs at the subsidiary level where appropriate, allowing Lobe shareholders to benefit from asset advancement while limiting dilution at the parent-company level. Cynaptec previously raised US$6 million to fund the L-130 program without the issuance of additional Lobe common shares.Dr. Frederick D. Sancilio, Ph.D., Chairman and Chief Executive Officer of Lobe Sciences, said, "Our decision to receive restricted shares reflects a simple view: we believe in Lobe, its programs, and its strategy. The Board and management chose restricted equity because we see meaningful value in increasing our ownership at this stage. Our focus remains on disciplined execution and building value for all shareholders.""I believe the Company's development platform and subsidiary model provide a disciplined path for advancing valuable pharmaceutical assets. Electing to receive equity reflects confidence in that plan and in the opportunity represented by the Company's subsidiary programs," said Dr. Harry Jacobson, Director of Lobe Sciences and Interim Chief Executive Officer of Applied Lipid Technologies, Inc.Mr. Wesley Ramjeet, Director of Lobe Sciences and Chair of the Audit Committee, said, "This settlement increases management and director ownership while preserving flexibility for the Company. From a governance and capital allocation perspective, the decision reflects confidence in Lobe's business plan and reinforces alignment between the Board, management, and shareholders."MI 61-101 MattersThe Debt Settlement is considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is exempt from the formal valuation requirement in Section 5.4 of MI 61-101 in reliance on Section 5.5(b) of MI 61-101, as the Company is not listed on a specified market within the meaning of MI 61-101. Additionally, the Debt Settlement is exempt from the minority approval requirement in Section 5.6 of MI 61-101 in reliance on Section 5.7(1)(a) of MI 61-101 insofar as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Settlement Shares issuable to related parties exceeds 25% of the Company's market capitalization.The Settlement Shares have not been and will not be registered under the U.S. Securities Act and may not be offered or sold in the United States, or to, or for the account or benefit of, U.S. persons or persons in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.Cynaptec Pharmaceuticals, Inc.: L-130 - CNS Therapeutic ProgramL-130 (psilocin mucate) is a patented, highly bioavailable, orally administered new chemical entity (NCE) designed as a stabilized form of psilocin, the active metabolite of psilocybin. The NCE is designed to provide enhanced stability, improved bioavailability, and more consistent circulating levels of psilocin, supporting reliable systemic exposure relative to traditional psilocybin-based approaches. Development of L-130 is being conducted by Cynaptec Pharmaceuticals, Inc., a subsidiary of the Company in which Lobe holds a 64% ownership interest.L-130 is initially being developed for the treatment of chronic cluster headache, a severe neurological condition with limited treatment options. The program is advancing in alignment with guidance received from the U.S. Food and Drug Administration following pre-IND interactions. Additional applications of L-130 are also progressing forward, consistent with the timeline provided on the Company's website.Applied Lipid Therapeutics LLC: S-100 - Sickle Cell Disease ProgramS-100 is an early-stage therapeutic candidate for sickle cell disease being developed through Applied Lipid Therapeutics LLC, a wholly owned subsidiary of the Company. It is designed to address underlying disease mechanisms using a lipid-based delivery platform, consisting of a unique blend of triglyceride esters of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), combined with a patented absorption-enhancing excipient system to improve bioavailability. The Company is advancing chemistry, manufacturing, and controls (CMC) activities to support production of clinical supply for a planned Phase 2a study. Orphan Drug designation has been applied for and is under review by the U.S. Food and Drug Administration.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE.For Further InformationDr. Frederick D. Sancilio
Chief Executive Officer
Lobe Sciences Ltd.
Email:

Lobe Sciences Announces Proposed Shares for Debt TransactionJune 1, 2026 10:00 PM
ACCESS NewswireVANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates for diseases with significant unmet medical needs, under a disciplined, pharmaceutical development platform, progressing assets from early development to clinical stages, through focused subsidiary companies, today announced that it has entered into agreements to settle C$1,372,761.20 in outstanding management and director fee debt through the issuance of an aggregate of 12,749,643 common shares of the Company (the "Settlement Shares") at a price of $0.11 per Settlement Share (the "Debt Settlement").This settlement transaction represents deferred management and director fees owed to certain directors and officers of the Company (collectively, the "Creditors"), which accrued pursuant to employment and consulting agreements between the Company and the Creditors.The Company's board of directors and management believe that completing the Debt Settlement by issuing shares, is in the best interests of the Company as it will allow the Company to preserve its cash resources for ongoing and planned operations.Completion of the Debt Settlement remains subject to receipt of all necessary regulatory approvals, including acceptance by the Canadian Securities Exchange (the "Exchange"). The Settlement Shares will be subject to a four-month hold period from the date of issuance in accordance with applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.MI 61-101 MattersThe Debt Settlement is considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is exempt from the formal valuation requirement in Section 5.4 of MI 61-101 in reliance on Section 5.5(b) of MI 61-101, as the Company is not listed on a specified market within the meaning of MI 61-101. Additionally, the Debt Settlement is exempt from the minority approval requirement in Section 5.6 of MI 61-101 in reliance on Section 5.7(1)(a) of MI 61-101 insofar as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Settlement Shares issuable to the Creditors exceeds 25% of the Company's market capitalization.The Settlement Shares have not been and will not be registered under the U.S. Securities Act and may not be offered or sold in the United States, or to, or for the account or benefit of, U.S. persons or persons in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.Cynaptec Pharmaceuticals, Inc.: L-130 - CNS Therapeutic ProgramL-130 (psilocin mucate) is a patented, highly bioavailable, orally administered new chemical entity (NCE) designed as a stabilized form of psilocin, the active metabolite of psilocybin. The NCE is designed to provide enhanced stability, improved bioavailability, and more consistent circulating levels of psilocin, supporting reliable systemic exposure relative to traditional psilocybin-based approaches. Development of L-130 is being conducted by Cynaptec Pharmaceuticals, Inc., a subsidiary of the Company in which Lobe holds a 64% ownership interest.L-130 is initially being developed for the treatment of chronic cluster headache, a severe neurological condition with limited treatment options. The program is advancing in alignment with guidance received from the U.S. Food and Drug Administration following pre-IND interactions.Applied Lipid Therapeutics LLC: S-100 - Sickle Cell Disease ProgramS-100 is an early-stage therapeutic candidate for sickle cell disease being developed through Applied Lipid Therapeutics LLC, a subsidiary of the Company. It is designed to address underlying disease mechanisms using a lipid-based delivery platform, consisting of a unique blend of triglyceride esters of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), combined with a patented absorption-enhancing excipient system to improve bioavailability. The Company is advancing chemistry, manufacturing, and controls (CMC) activities to support production of clinical supply for a planned Phase 2a study.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACYOR ADEQUACY OF THIS NEWS RELEASE.For Further InformationDr. Frederick D. Sancilio
Chief Executive Officer
Lobe Sciences Ltd.
Email:

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New YorkMay 6, 2026 8:00 PM
ACCESS NewswireVANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be attending the D. Boral Capital Global Conference being held on May 7, 2026 at The Plaza Hotel in New York City.Dr. Sancilio will be available for meetings with institutional investors, pharmaceutical companies, and potential strategic partners interested in learning more about Lobe's therapeutic programs and development strategy.Lobe identifies and advances therapeutic programs addressing significant unmet medical needs. The Company acquires preclinical and early-stage assets and advances them through focused subsidiary entities, each operating under a defined development and funding framework designed to efficiently achieve regulatory and clinical milestones. This model emphasizes formulation development, intellectual property protection, and engagement with regulatory authorities as programs progress through key value-inflection points.The Company is currently advancing two patented drug product candidates through this subsidiary approach:L-130 (psilocin mucate), a patented, highly bioavailable, orally administered new chemical entity (NCE) designed as a stabilized form of psilocin, the active metabolite of psilocybin. The NCE is designed to provide enhanced stability, improved bioavailability, and more consistent circulating levels of psilocin, supporting reliable systemic exposure relative to traditional psilocybin-based approaches. Development of L-130 is being conducted by Cynaptec Pharmaceuticals, Inc., a subsidiary of the Company in which Lobe holds a 64% ownership interest.S-100, an early-stage therapeutic candidate for sickle cell disease being developed through Applied Lipid Therapeutics LLC, also a subsidiary of the Company. It is designed to address underlying disease mechanisms using a lipid-based delivery platform, consisting of a unique blend of triglyceride esters of docosahexaenoic acid and eicosapentaenoic acid, combined with a patented absorption-enhancing excipient system to improve bioavailability. The Company is advancing chemistry, manufacturing, and controls (CMC) activities to support production of clinical supply for a planned Phase 2a study.Organizations interested in arranging a meeting with Dr. Sancilio during the conference may contact the Company at info@lobesciences.com to schedule an appointment.For Further InformationDr. Frederick D. Sancilio
Chief Executive Officer
Lobe Sciences Ltd.
Email:

Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational ProgressMay 6, 2026 6:00 AM
ACCESS NewswireVANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced its unaudited interim financial results for the second quarter of fiscal 2026 ended February 28, 2026 ("Q2 2026") and provided an operational update.During the quarter, the Company continued to advance its development pipeline while maintaining a disciplined approach to capital allocation. Management believes the progress achieved in Q2 2026 reflects continued execution on its strategic priorities and reinforces the Company's focus on building long-term shareholder value.Second Quarter 2026 Financial Highlights (as of February 28, 2026)Cash and Liquidity: Cash totaled $1,071,199, with additional short-term investments of $3,889,632, supporting ongoing development activities.Working Capital: Net working capital was $2,160,073.Research and Development: R&D expenses were $2,115,338 for the six months ended February 28, 2026, compared to $20,474 in the prior year period. The increase reflects advancement of the Company's core programs, Cynaptec's L-130 (psilocin mucate) program and Applied Lipid Therapeutic's S-100 (DHATG and EPATG) program.Operating Cash Flow: Cash used in operating activities was $2,637,862 for the six-month period, compared to $610,307 in the prior year, consistent with expanded development activities.Net Loss: Net loss for the quarter was $3,693,896, compared to $1,503,662 in the same period last year, primarily reflecting increased investment in R&D and corporate infrastructure.The financial and operational information outlined in this news release is derived from, and should be read in conjunction with, the Company's interim financial statements for Q2 2026 and the related management's discussion and analysis thereof, copies of which are available under the Company's profile on SEDAR+ at www.sedarplus.ca.CEO's Comments"During the first six months of fiscal 2026, we advanced both of our core subsidiary programs, L-130 through Cynaptec Pharmaceuticals and S-100 for sickle cell disease through Applied Lipid Therapeutics," said Dr. Fred Sancilio, CEO of Lobe Sciences Ltd. "Our approximately $2.1 million in R&D spend was driven primarily by external development work on L-130, while S-100 continued to move forward through focused internal efforts. We are also seeing increased market interest and inbound opportunities, but we are approaching these selectively and with discipline. Our priority remains straightforward: advance both programs in a measured way while maintaining control of our capital and building long-term value."Subsequent EventSubsequent to quarter-end, the Company completed a non-brokered private placement, issuing 14,615,384 common shares at $0.065 per share for gross proceeds of approximately $950,000. The financing was completed at pricing reflective of prevailing market conditions at the time and provides additional working capital to support the continued advancement of the Company's development programs.Cynaptec Pharmaceuticals, Inc.: L-130 - CNS Therapeutic ProgramL-130 (psilocin mucate) is a patented, highly bioavailable, orally administered new chemical entity (NCE) designed as a stabilized form of psilocin, the active metabolite of psilocybin. The NCE is designed to provide enhanced stability, improved bioavailability, and more consistent circulating levels of psilocin, supporting reliable systemic exposure relative to traditional psilocybin-based approaches. Development of L-130 is being conducted by Cynaptec Pharmaceuticals, Inc., a subsidiary of the Company in which Lobe holds a 64% ownership interest.L-130 is initially being developed for the treatment of chronic cluster headache, a severe neurological condition with limited treatment options. The program is advancing in alignment with guidance received from the U.S. Food and Drug Administration following pre-IND interactions.Applied Lipid Therapeutics LLC: S-100 - Sickle Cell Disease ProgramS-100 is an early-stage therapeutic candidate for sickle cell disease being developed through Applied Lipid Therapeutics LLC, a subsidiary of the Company. It is designed to address underlying disease mechanisms using a lipid-based delivery platform, consisting of a unique blend of triglyceride esters of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), combined with a patented absorption-enhancing excipient system to improve bioavailability. The Company is advancing chemistry, manufacturing, and controls (CMC) activities to support production of clinical supply for a planned Phase 2a study.For Further InformationDr. Frederick D. Sancilio
Chief Executive Officer
Lobe Sciences Ltd.
Email:

GLENSTAR DRILLING PROGRAM UPDATE AT WILDHORSE PROJECT CURRENTLY UNDERWAY IN NEVADAApril 29, 2026 1:21 PM
PR Newswire (US)

VANCOUVER, BC, April 29, 2026 /PRNewswire/ - Glenstar Minerals Inc. (CSE: GSTR) (OTCQB: GSTRF) (FRA: VO20) ("Glenstar" or the "Company") announces that the Phase 1 reverse circulation drill program at the Company's Wildhorse Project in Mineral County, Nevada, (see news release dated April 14, 2026) is underway and work is currently focused on the Rattlesnake Zone. Drilling began at the Coca Cola Zone and four (4) holes were completed in the target area during week one of the planned three-week program. A number of narrow intervals of strong alteration with local copper oxide mineralization were encountered prior to the drill rig being moved to the Rattlesnake Zone, which lies approximately 1,600 feet to the northeast of the Coca Cola Zone.







Hole RTSRC-1 intersected several multi meter scale intervals of strong oxide alteration/mineralization from surface to 345 feet. From 345 to 385 feet a partially oxidized zone of strong sulfide mineralization, quartz veinlets and silicification was intersected. Field identified sulfide minerals include chalcopyrite and fine-grained silver-grey minerals. The mineralized interval emits a strong odor of hydrogen sulfide. Sulfide abundance is estimated at 5%. Oxide minerals are present on fracture and range in color from yellow to orange to bright blue.Hole RTSRC-2 indicates multi-meter gossanous orange and red zones are prevalent from surface to 215 feet down hole (150 feet below the surface). From 215 feet to 245 feet, a 30 foot down hole interval returned an intense zone of oxide mineralization with abundant quartz veinlets was intersected. Preliminary conclusions of the drilling at Rattlesnake thus far indicate that we have successfully intersected the main Rattlesnake mineralized zone in a downdip position located 320 feet east of outcropping mineralized positions.Project Geologist and Exploration Manager Robert Marvin enthusiastically remarked, "To have intersected such a robust zone of poly sulfide mineralization in our first hole at Rattlesnake is very encouraging. It is becoming clear that a well foliated, fine grained, grey hornfels formation at Rattlesnake is an excellent mineralization host rock, based on the early visual results of the drill program. This rock type lies in the hanging wall of a thrust fault which daylights at a poly metallic zone worked historically by several shallows and declines. Strong quartz veinlet development and sulfide mineralization are contained within and above the thrusted contact. RTSRC-1 intersected 10+ meters (down hole interval) of strong silicification, veining, and partially oxidized sulfide mineralization in a position 105 meters down dip of the historic workings. This validates our target model and we are hopeful of further success in the remainder of the Phase 1 drill program at Rattlesnake."All observations of intervals of alteration and sulfide mineralization represent down hole intervals and it should be noted that Glenstar does not have sufficient data to report true intercept widths at this time. The drilling at Wildhorse is expected to continue for another 7 to 10 days, at which time all of the samples will be shipped to Paragon Geochemical Inc in Sparks Nevada for assay analysis.Project BackgroundThe Wildhorse Property is comprised of 89 mineral claims, representing 1,780 acres (720 hectares) in Mineral County, Nevada, and was initially targeted after compilation of all available data, including notes of a 1975 field examination contained in the Anaconda Company archives housed at the university of Wyoming. The claims show historical workings that appear to date from the late 1800's and early 1900's. Other claim stakes that the geological team discovered on the property indicate the last time the area was staked was 2011, however, these claims were never registered with the BLM. Preliminary geological assessment of the claims, and the area in general, indicate there are a series of east dipping mineralized zones. Initial field examination of the property identified and sampled a quartz veinlet zone containing in excess of 1 gram per ton gold, 1% copper, and 6,100 ppm of antimony. It was also reported that outcropping zones also contain bismuth and tungsten, which points to a focused intrusive source for the epidote skarn alteration and poly-metallic system (see news release dated February 11, 2025).About Glenstar Minerals Inc.Glenstar is a mineral exploration company with a focus on polymetallic minerals. These elements are classified as critical minerals and are essential in the manufacturing of sophisticated electronics and other vital energy technologies. The Company's mission is to leverage its knowledge and connections to explore, acquire, and develop critical mineral and energy metal properties throughout the world.Glenstar's shares trade on the Canadian Securities Exchange (CSE) under the symbol "GSTR", on the Frankfurt Stock Exchange under the symbol "VO20", and on the Over-the-Counter market (OTCQB) in the United States under the symbol "GSTRF".Robert Marvin, P.Geo (ONT) is the qualified person as defined by National Instrument 43-101 and is the independent consulting geologist for Glenstar Minerals Inc. who has examined the Green Monster and Wildhorse properties on the ground numerous times since 2022 and 2024 respectively. All fieldwork relating to geologic observations and sampling as reported herein, has been directly overseen by Mr. Marvin who supervised the preparation of, and has reviewed and approved, the technical information in this release.ON BEHALF OF THE BOARD"David Ryan"
President & CEOFurther information regarding the Company can be found on SEDAR+ at www.sedarplus.ca, by visiting the Company's website at www.glenstar.ca or by contacting the Company directly at 604-449-2810.Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Information Certain information contained in this news release constitutes "forward-looking information" or "forward-looking statements" (collectively, "forward- looking information"). Without limiting the foregoing, such forward-looking information includes statements regarding the process and completion of any Offering, the use of proceeds of the Offering and any statements regarding the Company's business plans, expectations and objectives. In this news release, words such as "may", "would", "could", "will", "likely", "believe", "expect", anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking information.Forward-looking information should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Mineral exploration is subject to risks and uncertainties and there is no assurance that any potential results or findings that may be suggested in this press release will ultimately happen. Forward-looking information is based on information available at the time and/or the Company management's good faith belief with respect to future events and is subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. For additional information with respect to these and other factors and assumptions underlying the forward-looking information made in this news release, see the Company's most recent Management's Discussion and Analysis and financial statements and other documents filed by the Company with the Canadian securities commissions and the discussion of risk factors set out therein. Such documents are available at www.sedarplus.ca under the Company's profile and on the Company's website. The forward-looking information set forth herein reflects the Company's expectations as at the date of this news release and is subject to change after such date. This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of the Company and certain of the plans and objectives of the Company with respect to the same. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. We seek safe harbour.



View original content to download multimedia:https://www.prnewswire.com/news-releases/glenstar-drilling-program-update-at-wildhorse-project-currently-underway-in-nevada-302757656.htmlSOURCE Glenstar Minerals Inc

Original: GLENSTAR DRILLING PROGRAM UPDATE AT WILDHORSE PROJECT CURRENTLY UNDERWAY IN NEVADA

Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications ServicesApril 21, 2026 6:00 AM
ACCESS NewswireVANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs, is pleased to announce that it has engaged Massive Intelligence Pty Ltd ("Massive Intelligence") to provide investor relations and corporate communications services.Pursuant to an engagement letter dated April 15th 2026, the Company has retained Massive Intelligence for an initial term of three (3) months, commencing April 15, 2026, with the option to renew for a further six (6) months subject to written agreement of the parties.Massive Intelligence will provide investor relations and promotional services on behalf of the Company, including the development of investor materials and corporate communications content, distributed via social media channels, email and press releases. The Company will pay Massive Intelligence a fixed monthly cash retainer over the course of the engagement. During the initial three-month term, this equates to a total of US$11,800, paid in monthly installments. If the agreement is renewed, the Company will commit an additional US$31,500 over the subsequent six-month period, also paid monthly. No securities of the Company will be issued in connection with this engagementMassive Intelligence is arm's length to Lobe Sciences. To the Company's knowledge, neither Massive Intelligence nor any of its directors, officers, or employees currently holds any securities of the Company or has any right or intent to acquire such securities, other than securities that may be purchased through the open market. Massive Intelligence is not a registered dealer or adviser under applicable securities legislation.Massive Intelligence is based in Melbourne, Australia. The lead representative for Massive Intelligence is Angus Kennelly, Managing Director, who can be reached at angus@massiveintelligence.com.au or +61 413 541 301.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE.About Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)Lobe Sciences Ltd. is clinical stage biopharmaceutical company advancing programs in diseases with unmet medical needs. The Company is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals, Inc. and wholly owned subsidiary Applied Lipid Technologies Inc. (Formerly Altemia, Inc.).About Cynaptec Pharmaceuticals, Inc.Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders. Cynaptec's initial development program is focused on the use of its proprietary L-130 (psilocin mucate) compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders. Cynaptec is 64% owned by Lobe.About L-130 (psilocin mucate)L-130 is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions. Whereas conventional psilocin is an unstable compound that has been challenging for the industry to develop as a standalone pharmaceutical, L-130's stability and bioavailability profile, and associated safety and efficacy signals, suggest the potential for prescription drug development in a variety of neurological and psychiatric indications.About Applied Lipid Technologies, Inc.Applied Lipid Technologies, Inc., a wholly owned subsidiary of Lobe Sciences Ltd., is a biopharmaceutical company focused on developing novel lipid therapeutics to address unmet medical needs. The Company is advancing S-100, a complex lipid, self-emulsifying oral dosage formulation, as a drug candidate for the treatment of sickle cell disease. Patents covering the formulation have been issued, with additional applications pending. A Phase 2a clinical program may commence in early 2027. Applied Lipid Technologies was previously known as Altemia, Inc.For Further InformationDr. Frederick D. Sancilio
Chief Executive Officer
Lobe Sciences Ltd.
Email:

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate UpdateApril 20, 2026 6:00 AM
ACCESS NewswireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce the closing of its previously announced non-brokered private placement offering of 14,615,384 common shares in the capital of the Company ("Common Shares") at a price of $0.065 per Common Share, for aggregate gross proceeds of approximately $950,000 (the "Private Placement").The Company intends to use the proceeds of the Private Placement for working capital and general corporate purposes, and to advance its S-100 drug candidate for the treatment of sickle cell disease. A portion of the proceeds will be directed to its subsidiary, Applied Lipid Technologies, Inc., to support development of the S-100 program toward human clinical trials. The Company has procured the active pharmaceutical ingredient required for these studies, enabling the program to move forward.All securities issued in connection with the Private Placement will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.None of the securities sold under the Private Placement have been or will be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE.About Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE)Lobe Sciences Ltd. is a biopharmaceutical company advancing programs in diseases with unmet medical needs. The Company is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals, Inc. and wholly owned subsidiary Applied Lipid Technologies Inc. (Formerly Altemia, Inc.).About Cynaptec Pharmaceuticals, Inc.Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders. Cynaptec's initial development program is focused on the use of its proprietary L-130 (psilocin mucate) compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders. Cynaptec is 64% owned by Lobe.About L-130 (psilocin mucate)L-130 is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions. Whereas conventional psilocin is an unstable compound that has been challenging for the industry to develop as a standalone pharmaceutical, L-130's stability and bioavailability profile, and associated safety and efficacy signals, suggest the potential for prescription drug development in a variety of neurological and psychiatric indications.For Further InformationDr. Frederick D. Sancilio
Chief Executive Officer
Lobe Sciences Ltd.
Email:

Drilling Results at Green Monster Project Show Geologically Complex Polymetallic StructureApril 17, 2026 8:29 AM
NewsfileVancouver, British Columbia--(Newsfile Corp. - April 17, 2026) - Glenstar Minerals Inc. (CSE: GSTR) (OTCQB: GSTRF) (FSE: VO20) ("Glenstar" or the "Company") announces that assay results of the Phase 2 drill program at the Company's Green Monster Project in Nevada continue to show polymetallic mineralization along the trend line that was drilled in the Phase 1 drill program. Numerous polymetallic zones were encountered during the Phase 2 program, which consisted of six (6) holes drilled to depths from 500 feet to 585 feet encompassing ~3,320 feet of total drilling across three (3) drill pads. These holes contained highly fractured rock with abundant clay alteration and brightly coloured orange and red oxide minerals and decalcification. Assay results confirmed that the area of interest is significantly mineralized and geologically complex; however, at this early stage of exploration the grades reported are less than expected while at the same time raising a number of interesting questions. As a result of this geological complexity, further geophysical work is required to address the data that is inconclusive and provide a clearer understanding of the type of structure and system contained within the property.To gain a more detailed understanding the Company will continue to embrace the latest available technology by utilizing a Terean geophysical survey. This type of survey is cost effective and highly successful in mapping faults and structural controls on mineralization, defining depth to competent rock, quantifying overburden, imaging paleochannels & alteration zones, and identifying weathered and fractured zones that could indicate the presence of large faults and their orientation.Glenstar Geologist Bob Marvin remarked that, "While the results of the Phase 2 program were not as exciting as we were expecting, the complexity of the structure is, nevertheless, incredibly interesting. It raises a number of questions that need to be answered in order to gain a better understanding of what we are actually dealing with. The Terean survey will provide a plethora of information that will determine what the next phase of exploration will look like." Project Background & Recent Exploration WorkThe Green Monster Property is comprised of 35 federal lode claims covering ~700 acres located in Clark County, Nevada, on the west trending spur of the Spring Mountains and is approximately 40 miles southwest of Las Vegas. Until the recent drill program in May of 2025, no drilling was ever conducted on the property, but the Company's previous identification of robust nickel-copper with anomalous cobalt from sampling work done in 2022 indicated that several targets were ideal for shallow RC drilling (see news releases dated May 28, 2025, and July 16, 2025).Glenstar acquired the Green Monster Property and conducted initial groundwork in 2022 that included reconnaissance geologic mapping, surface rock sampling, soil sampling, and a drone magnetic survey. Channel sampling across the exposed back of a raise off the main shaft returned 1.18 meters of 3.77% Cu (Copper), 3.06% Ni (Nickel), 0.21% Co (Cobalt) and 6.83% Zn (Zinc). These values are well in excess of select dump samples from historical underground workings and represent in-place, vein style mineralization. Sampling of oxide and sulfide bearing boulders directly downhill of the patented workings has confirmed the presence of very high zinc (>10%) and silver (>200ppm), as well as copper, uranium, and lead. (Sampling results provided above were previously published in the Green Monster Project NI 43-101 Technical Report dated June 20, 2023, Section 7.5).About Glenstar Minerals Inc.Glenstar is a mineral exploration company with a focus on polymetallic minerals. These elements are classified as critical minerals and are essential in the manufacturing of sophisticated electronics and other vital energy technologies. The Company's mission is to leverage its knowledge and connections to explore, acquire, and develop critical mineral and energy metal properties throughout the world.Glenstar's shares trade on the Canadian Securities Exchange (CSE) under the symbol "GSTR", on the Frankfurt Stock Exchange under the symbol "VO20", and on the Over-the-Counter market (OTCQB) in the United States under the symbol "GSTRF".Robert Marvin, P.Geo (ONT) is the qualified person as defined by National Instrument 43-101 and is the independent consulting geologist for Glenstar Minerals Inc., who has examined the Green Monster and Wildhorse properties on the ground numerous times since 2022 and 2024 respectively. All fieldwork relating to geologic observations and sampling as reported herein, has been directly overseen by Mr. Marvin who supervised the preparation of, and has reviewed and approved, the technical information in this release.ON BEHALF OF THE BOARD"David Ryan"
President & CEOFurther information regarding the Company can be found on SEDAR+ at www.sedarplus.ca, by visiting the Company's website at www.glenstar.ca or by contacting the Company directly at 604-449-2810.Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.Cautionary Statement Regarding Forward-Looking Information Certain information contained in this news release constitutes "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information"). Without limiting the foregoing, such forward-looking information includes statements regarding the process and completion of any Offering, the use of proceeds of the Offering and any statements regarding the Company's business plans, expectations and objectives. In this news release, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking information. Forward-looking information should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Mineral exploration is subject to risks and uncertainties and there is no assurance that any potential results or findings that may be suggested in this press release will ultimately happen. Forward-looking information is based on information available at the time and/or the Company management's good faith belief with respect to future events and is subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. For additional information with respect to these and other factors and assumptions underlying the forward-looking information made in this news release, see the Company's most recent Management's Discussion and Analysis and financial statements and other documents filed by the Company with the Canadian securities commissions and the discussion of risk factors set out therein. Such documents are available at www.sedarplus.ca under the Company's profile and on the Company's website. The forward-looking information set forth herein reflects the Company's expectations as at the date of this news release and is subject to change after such date. This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of the Company and certain of the plans and objectives of the Company with respect to the same. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state in the United States in which such offer, solicitation or sale would be unlawful. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This release may contain statements within the meaning of safe harbour provisions as defined under securities laws and regulations. We seek safe harbour.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293052
Original: Drilling Results at Green Monster Project Show Geologically Complex Polymetallic Structure

ASSAY RESULTS REPORT HIGH GRADE GOLD ENCOUNTERED IN COCA COLA ZONE TRENCHING PROGRAM AT WILDHORSE PROJECT; PHASE 1 DRILLING BEGINSApril 14, 2026 10:46 AM
PR Newswire (US)

VANCOUVER, BC, April 14, 2026 /PRNewswire/ - Glenstar Minerals Inc. (CSE: GSTR) (OTCQB: GSTRF) (FRA: VO20) ("Glenstar" or the "Company") announces that it has received assay results from the trenching work undertaken at the Wildhorse Project in Mineral County, Nevada in late February, and that the Phase 1 drill program has begun.







Coca Cola TrenchingAssay results from trench #1 at the Coca Cola Zone show that high grade gold, with one sample measuring 23.6 g/t, was discovered in deep red oxidized material contained within a structural zone trending east-west. This trend of red oxidation has been traced uphill in a linear belt that is at least 100 meters in strike length. The exact nature of the host rock of the oxide mineralization has not been confirmed as yet, however, this gold rich style and mapped trend of mineralization is a focus of the Phase 1 drilling plan at the Coca Cola Zone.Also reported was an average of ~1% copper within the same deep red oxidized structure containing the gold results and is deemed to be of considerable interest. Assay results from samples taken from Trench #2, which is lower down the incline from Trench #1, proved to be unremarkable and suggests that the trend may end at its location or that it dips dramatically vertical. This information is beneficially relevant to the plan of drill placement, which will follow the trend to the east of the trenches.Wildhorse Drill Program CommencesMidnight Sun Drilling Inc. ("MSD") mobilized to the property late last week and reverse circulation drilling began over the weekend. Six (6) drill sites were permitted for the Coca Cola Zone which will test the east-west trend discovered in the trenching program. Each drill site is anticipated to accommodate an initial hole that is planned to be drilled to a depth of up to ~500 feet. However, the number of holes drilled at each site could be increased in order to follow mineralization that may be encountered and observed at various depths downhole. Any additional holes at each site would be drilled at different angles from surface to help determine the possible extent and trend of mineralization that may be encountered.Seven (7) drill sites are permitted for the Rattlesnake Zone, which lies approximately 1,600 feet to the northeast of the Coca Cola Zone, and each site is planned to be drilled to a depth of 300 to 500 feet. The initial holes at each site at Rattlesnake are planned to be vertical and will follow the north-south mineralization direction encountered during previous field work. As with the Coca Cola Zone however, additional holes could be drilled at each site at varying angles to follow and test any observable mineralization. The Rattlesnake Zone is centered on historic workings and dump samplings that have returned results of >100 g/t silver along with 1 g/t gold, 3% copper, 0.59% antimony, and 256 ppm tungsten. The Rattlesnake Zone strikes north-south and dips ~20 degrees to the east and the Company is targeting the down-dip continuation to the east of the historically worked exposures.Initial drilling has begun at the Coca Cola Zone and once completed will then move to the Rattlesnake Zone. The entire drill program at the Wildhorse Project is expected to take approximately 21 days.Project Geologist Bob Marvin stated that, "The data compiled thus far from the two zones at Wildhorse suggest that we have two different systems; Coca Cola trending east-west with gold and copper being prevalent, and Rattlesnake trending north-south which has presented very encouraging tungsten and antimony numbers from sampling along with high silver and copper. This could represent an ideal polymetallic target that is pretty robust and definitely meter scale".Project BackgroundThe Wildhorse Property is comprised of 89 mineral claims, representing 1,780 acres (720 hectares) in Mineral County, Nevada, and was initially targeted after compilation of all available data, including notes of a 1975 field examination contained in the Anaconda Company archives housed at the university of Wyoming. The claims show historical workings that appear to date from the late 1800's and early 1900's. Other claim stakes that the geological team discovered on the property indicate the last time the area was staked was 2011, however, these claims were never registered with the BLM. Preliminary geological assessment of the claims, and the area in general, indicate there are a series of east dipping mineralized zones. Initial field examination of the property identified and sampled a quartz veinlet zone containing in excess of 1 gram per ton gold, 1% copper, and 6,100 ppm of antimony. It was also reported that outcropping zones also contain bismuth and tungsten, which points to a focused intrusive source for the epidote skarn alteration and poly-metallic system (see news release dated February 11, 2025).About Glenstar Minerals Inc.Glenstar is a mineral exploration company with a focus on polymetallic minerals. These elements are classified as critical minerals and are essential in the manufacturing of sophisticated electronics and other vital energy technologies. The Company's mission is to leverage its knowledge and connections to explore, acquire, and develop critical mineral and energy metal properties throughout the world.Glenstar's shares trade on the Canadian Securities Exchange (CSE) under the symbol "GSTR", on the Frankfurt Stock Exchange under the symbol "VO20", and on the Over-the-Counter market (OTCQB) in the United States under the symbol "GSTRF".Robert Marvin, P.Geo (ONT) is the qualified person as defined by National Instrument 43-101 and is the independent consulting geologist for Glenstar Minerals Inc. who has examined the Green Monster and Wildhorse properties on the ground numerous times since 2022 and 2024 respectively. All fieldwork relating to geologic observations and sampling as reported herein, has been directly overseen by Mr. Marvin who supervised the preparation of, and has reviewed and approved, the technical information in this release.ON BEHALF OF THE BOARD"David Ryan"
President & CEOFurther information regarding the Company can be found on SEDAR+ at www.sedarplus.ca, by visiting the Company's website at www.glenstar.ca or by contacting the Company directly at 604-449-2810.Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Information Certain information contained in this news release constitutes "forward-looking information" or "forward-looking statements" (collectively, "forward- looking information"). Without limiting the foregoing, such forward-looking information includes statements regarding the process and completion of any Offering, the use of proceeds of the Offering and any statements regarding the Company's business plans, expectations and objectives. In this news release, words such as "may", "would", "could", "will", "likely", "believe", "expect", anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking information.Forward-looking information should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved.  Mineral exploration is subject to risks and uncertainties and there is no assurance that any potential results or findings that may be suggested in this press release will ultimately happen. Forward-looking information is based on information available at the time and/or the Company management's good faith belief with respect to future events and is subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. For additional information with respect to these and other factors and assumptions underlying the forward-looking information made in this news release, see the Company's most recent Management's Discussion and Analysis and financial statements and other documents filed by the Company with the Canadian securities commissions and the discussion of risk factors set out therein. Such documents are available at www.sedarplus.ca under the Company's profile and on the Company's website. The forward-looking information set forth herein reflects the Company's expectations as at the date of this news release and is subject to change after such date. This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of the Company and certain of the plans and objectives of the Company with respect to the same. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. We seek safe harbour.



View original content to download multimedia:https://www.prnewswire.com/news-releases/assay-results-report-high-grade-gold-encountered-in-coca-cola-zone-trenching-program-at-wildhorse-project-phase-1-drilling-begins-302741888.htmlSOURCE Glenstar Minerals Inc

Original: ASSAY RESULTS REPORT HIGH GRADE GOLD ENCOUNTERED IN COCA COLA ZONE TRENCHING PROGRAM AT WILDHORSE PROJECT; PHASE 1 DRILLING BEGINS

Lobe Sciences Ltd. Announces Non-Brokered Private PlacementApril 10, 2026 8:00 PM
ACCESS NewswireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.VANCOUVER, BC / ACCESS Newswire / April 10, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce a non-brokered private placement offering of 14,615,384 common shares in the capital of the Company ("Common Shares") at a price of $0.065 per Common Share, for aggregate gross proceeds of approximately $950,000 (the "Private Placement").The Company intends to use the net proceeds of the Private Placement to fund working capital and general corporate expenses.The Private Placement remains subject to receipt of all necessary regulatory approvals, including Exchange acceptance. All securities issued in connection with the Private Placement will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.None of the securities to be sold under the Private Placement have been or will be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.NEITHER THE CANADIANSECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWEDOR ACCEPT RESPONSIBILITY FOR THE ACCURACYOR ADEQUACY OF THIS NEWS RELEASE.About Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F)Lobe Sciences Ltd. is a biopharmaceutical company advancing programs in diseases with unmet medical needs. The Company is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals, Inc. and wholly owned subsidiary Applied Lipid Technologies Inc. (Formerly Altemia, Inc.).About Cynaptec Pharmaceuticals, Inc.Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders. Cynaptec's initial development program is focused on the use of its proprietary L-130 (psilocin mucate) compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders. Cynaptec is 64% owned by Lobe.About L-130 (psilocin mucate)L-130 is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions. Whereas conventional psilocin is an unstable compound that has been challenging for the industry to develop as a standalone pharmaceutical, L-130's stability and bioavailability profile, and associated safety and efficacy signals, suggest the potential for prescription drug development in a variety of neurological and psychiatric indications.For Further InformationDr. Frederick D. Sancilio
Chief Executive Officer
Lobe Sciences Ltd.
Email:

GLENSTAR RECEIVES APPROVAL FOR EXTENSIVE DRILL PROGRAM AT WILDHORSE TUNGSTEN-COPPER-POLYMETALLIC PROJECT IN NEVADAApril 1, 2026 1:29 PM
PR Newswire (US)

13 Hole Drill Plan on Two Exploration Sites2,200 Feet of New Road ConstructionDriller Contracted







VANCOUVER, BC, April 1, 2026 /PRNewswire/ - Glenstar Minerals Inc. (CSE: GSTR) (OTCQB: GSTRF) (FRA: VO20) ("Glenstar" or the "Company") announces that it has received approval from the Bureau of Land Management ("BLM") to conduct a thirteen (13) hole reverse circulation drill program at it's Wildhorse Project in Mineral County, Nevada. The BLM approval also provides for the construction of 2,200 feet of additional access road(s) to the drill sites, to complement existing land access to the exploration areas and planned drill target sites.The Company has also contracted Midnight Sun Drilling Inc. ("MSD") to conduct the drill program at Wildhorse. MSD is a well-established drilling company in business for over 50 years, with offices in the Yukon, Alaska, and Nevada that has previously worked with Glenstar on the Green Monster Project in southern Nevada in May of 2025, which confirmed the presence of anomalous Nickel-Copper-Cobalt-Zinc that was reported from previous channel sampling results (see news release dated April 22, 2025 and May 28, 2025).Assay results from the recent trenching program at Wildhorse that was conducted in late February are still pending from ALS Chemex, however, visual examination of the bedrock that was uncovered in the trenches during this program confirmed what previous surface sampling suggested was occurring geologically at Wildhorse. The Company anticipates receiving these assay results at any time (see news release dated March 10, 2026).The Wildhorse Project drill plan will be comprised of six (6) holes at the Coca Cola Zone and seven (7) holes at the Rattlesnake Zone. The Company is very enthusiastic to initiate drilling at both of these zones at Wildhorse following the recent trenching that occurred at the Coca Cola Zone, that resulted in defining the bedrock orientation of a meter scale zone of quartz veining, and copper oxide and sulfide mineralization. Trenching also exposed a wider width of alteration than initially anticipated and the trend of mineralization that continued throughout the exposed bedrock was significant and is considered to be very encouraging.Coca Cola Zone The six planned drill holes at the Coca Cola Zone will follow the mineralized trend that was uncovered during previous sampling work conducted to the east of the trenches, where select assay results returned copper values of 1.6%, 5.3%, 2.3% and 5.1%, along with an average of 21.6 ppm silver. Additionally, the samples are anomalous in bismuth - averaging 156 ppm across four samples, and also tungsten – which averaged 72.5 ppm across the same samples. Geologic observations of this zone include the presence of a complex array of narrow porphyritic dikes with feldspar phenocrysts in a black, fine-grained matrix. By compiling the results of the phase one rock sampling work and geologic observations from the trenching program, a clear picture of property scale geological, alteration, and mineralization zoning is emerging. The central portion of the property contains complex porphyritic intrusions within a strong skarnified envelope. High grade copper and silver, along with strongly anomalous tungsten, bismuth, and antimony in the central portion are surrounded by strong zinc and lead mineralization in areas more distal from the center of the system, as it is understood at this early stage of exploration of the property (see news release of July 23, 2025).Trenching also showed that what was originally thought to be a north-south trend of mineralization was intersected by the newly uncovered east-west trend of highly fractured and altered rock that appears to continue beyond the trenches. This new trending information has confirmed the drill hole locations for this first phase of drilling at the Coca Cola Zone. The six hole drill plan will follow the mineralized trend line for ~500 feet from the east sampling zone to the west trench area, and each hole will be drilled to a depth of up to 500 feet at various angles yet to be fully determined.Rattlesnake ZoneThe seven drill holes planned for the Rattlesnake Zone, which lies approximately 1,600 feet to the northeast of the Coca Cola Zone, will each be drilled to a depth of 300 to 500 feet, however, these holes will be vertical in nature and follow the north-south mineralization direction encountered during previous field work.Property scale zoning of gold, silver, tungsten, bismuth, tellurium, and base metals suggest the center of the mineralized system at the Wildhorse Project lies around and between the Rattlesnake and Coca Cola Zones, and may extend under cover to the east and west of these outcropping areas. Data compiled thus far suggests that there could be in excess of 1 km of strike length between these two zones and the drill plan is designed to test the degree and extent of similar mineralization at each zone and delineate the magnitude of the potential skarn system and the expected underlying porphyry system (see news release of September 24, 2025).Project Geologist Bob Marvin remarked that, "We are quite pleased with the quick turnaround from the BLM in approving the drill program and new road access construction. The addition of Midnight Sun Drilling to the project is fantastic as we have worked very successfully with them at the Green Monster Project. Personally, I am quite excited to kick off this next stage of exploration drilling to see how significant the extent of polymetallic mineralization, and tungsten in particular, at Wildhorse truly is."Project Background & Recent Exploration WorkThe Wildhorse Property is comprised of 89 mineral claims, representing 1,780 acres (720 hectares) in Mineral County, Nevada, and was initially targeted after compilation of all available data, including notes of a 1975 field examination contained in the Anaconda Company archives housed at the university of Wyoming. The claims show historical workings that appear to date from the late 1800's and early 1900's. Other claim stakes that the geological team discovered on the property indicate the last time the area was staked was 2011, however, these claims were never registered with the BLM. Preliminary geological assessment of the claims, and the area in general, indicate there are a series of east dipping mineralized zones. Initial field examination of the property identified and sampled a quartz veinlet zone containing in excess of 1 gram per ton gold, 1% copper, and 6,100 ppm of antimony. It was also reported that outcropping zones also contain bismuth and tungsten, which points to a focused intrusive source for the epidote skarn alteration and poly-metallic system (see news release dated February 11, 2025).About Glenstar Minerals Inc.Glenstar is a mineral exploration company with a focus on polymetallic minerals. These elements are classified as critical minerals and are essential in the manufacturing of sophisticated electronics and other vital energy technologies. The Company's mission is to leverage its knowledge and connections to explore, acquire, and develop critical mineral and energy metal properties throughout the world.Glenstar's shares trade on the Canadian Securities Exchange (CSE) under the symbol "GSTR", on the Frankfurt Stock Exchange under the symbol "VO20", and on the Over-the-Counter market (OTCQB) in the United States under the symbol "GSTRF".Robert Marvin, P.Geo (ONT) is the qualified person as defined by National Instrument 43-101 and is the independent consulting geologist for Glenstar Minerals Inc. who has examined the Green Monster and Wildhorse properties on the ground numerous times since 2022 and 2024 respectively. All fieldwork relating to geologic observations and sampling as reported herein, has been directly overseen by Mr. Marvin who supervised the preparation of, and has reviewed and approved, the technical information in this release.ON BEHALF OF THE BOARD"David Ryan"
President & CEOFurther information regarding the Company can be found on SEDAR+ at www.sedarplus.ca, by visiting the Company's website at www.glenstar.ca or by contacting the Company directly at 604-449-2810.Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Information Certain information contained in this news release constitutes "forward-looking information" or "forward-looking statements" (collectively, "forward- looking information"). Without limiting the foregoing, such forward-looking information includes statements regarding the process and completion of any Offering, the use of proceeds of the Offering and any statements regarding the Company's business plans, expectations and objectives. In this news release, words such as "may", "would", "could", "will", "likely", "believe", "expect", anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking information.Forward-looking information should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved.  Mineral exploration is subject to risks and uncertainties and there is no assurance that any potential results or findings that may be suggested in this press release will ultimately happen. Forward-looking information is based on information available at the time and/or the Company management's good faith belief with respect to future events and is subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. For additional information with respect to these and other factors and assumptions underlying the forward-looking information made in this news release, see the Company's most recent Management's Discussion and Analysis and financial statements and other documents filed by the Company with the Canadian securities commissions and the discussion of risk factors set out therein. Such documents are available at www.sedar.com under the Company's profile and on the Company's website. The forward-looking information set forth herein reflects the Company's expectations as at the date of this news release and is subject to change after such date. This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of the Company and certain of the plans and objectives of the Company with respect to the same. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. We seek safe harbour.



View original content to download multimedia:https://www.prnewswire.com/news-releases/glenstar-receives-approval-for-extensive-drill-program-at-wildhorse-tungsten-copper-polymetallic-project-in-nevada-302731731.htmlSOURCE Glenstar Minerals Inc

Original: GLENSTAR RECEIVES APPROVAL FOR EXTENSIVE DRILL PROGRAM AT WILDHORSE TUNGSTEN-COPPER-POLYMETALLIC PROJECT IN NEVADA

Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial OfficerMarch 9, 2026 12:00 AM
ACCESS NewswireVANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with principal executive offices in Florida. The Company identifies and advances therapeutic programs addressing significant unmet medical needs. Lobe is pleased to announce the promotion of Mr. Mirza Rahimani to Chief Financial Officer, effective March 2, 2026. Mr. Rahimani has been working with the Company since December 1, 2025, providing financial advisory services to management and the Board of Directors, and is now assuming the role of Chief Financial Officer.Mr. Rahimani is a seasoned finance executive with over fifteen years of experience in accounting, financial reporting, corporate governance, and corporate development. His experience includes supporting early and growth-oriented companies through complex transactions, debt and equity financings, mergers and acquisitions, and ongoing public-company compliance requirements.Mr. Rahimani has served in senior finance roles across a range of industries including life sciences, mining, and technology, and has extensive experience working with public companies. His background includes advising management teams and boards on financial reporting under IFRS and US GAAP, strengthening internal control frameworks, and supporting corporate development initiatives and strategic transactions. He has held Director and Officer positions with several publicly listed Canadian companies.Dr. Frederick Sancilio, Chairman and Chief Executive Officer of the Company commented, "We are very pleased to promote Mirza to the position of Chief Financial Officer after working closely with him over the past several months, during which he has served as a financial advisor to both me and the Board. Mirza has already developed a strong understanding of the Company's strategy and operations. He brings extensive experience in public-company financial reporting, corporate governance and corporate development, and his background supporting growth-oriented companies through strategic transactions, financings and regulatory compliance will be an important asset as we continue to advance the Company's strategy and create value for our shareholders."Mr. Rahimani is a Chartered Professional Accountant (CPA, CA) and holds a Bachelor of Commerce degree from the Sauder School of Business at the University of British Columbia. He succeeds Mr. Yong Yao, who previously served as the Company's Chief Financial Officer through an arrangement with Century Biolabs Inc.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACYOR ADEQUACY OF THIS NEWS RELEASE.About Lobe Sciences Ltd.Lobe Sciences Ltd. is a biopharmaceutical company advancing programs in diseases with unmet medical needs. The Company is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals, Inc. and wholly owned subsidiary Applied Lipid Technologies, Inc. (formerly Altemia, Inc.). For Further InformationDr. Frederick D. Sancilio
Chief Executive Officer
Lobe Sciences Ltd.
Email:

Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare ConferencesMarch 5, 2026 7:40 AM
ACCESS NewswireVANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 5, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with principal executive offices in Florida. The Company identifies and advances therapeutic programs addressing significant unmet medical needs.The Company announces that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be in Miami, Florida during the upcoming Jefferies and Leerink Healthcare Conferences and will be available for meetings with investors, pharmaceutical companies, and organizations interested in learning more about the Company and its programs.Lobe acquires preclinical and early-stage therapeutic assets and places them within focused subsidiary entities. Each program follows a defined development and funding structure designed to support advancement through regulatory and clinical milestones. The Company's approach includes formulation development, intellectual property protection, and engagement with regulatory authorities as programs advance through clinical evaluation and value-inflection points in a cost-efficient manner.Lobe is currently advancing two patented assets through this subsidiary approach: L-130, targeting chronic cluster headache, and S-100, focused on sickle cell disease. Additional programs under evaluation include therapies for substance use disorder and other neurological indications.Organizations interested in arranging a meeting with Dr. Sancilio while he is in Miami may contact the Company by email at partnerships@lobesciences.com to schedule an appointment.About Lobe Sciences Ltd.Lobe Sciences Ltd. is a biopharmaceutical company advancing programs in diseases with unmet medical needs. The Company is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals, Inc. and wholly owned subsidiary Applied Lipid Technologies, Inc. (formerly Altemia, Inc.).About Cynaptec Pharmaceuticals, Inc.Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders. Cynaptec's initial development program is focused on the use of its proprietary L-130 (psilocin mucate) compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders. Cynaptec is 64% owned by Lobe.About L-130 (psilocin mucate)L-130 is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy. Conventional psilocin has historically been difficult to develop as a pharmaceutical due to stability limitations; the L-130 compound was developed to address these challenges.For Further InformationDr. Frederick D. Sancilio
Chief Executive Officer
Lobe Sciences Ltd.
Email:

Lobe Sciences Reports First Quarter 2026 Results and HighlightsFebruary 3, 2026 7:00 AM
ACCESS NewswireVANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited financial results for the first quarter of fiscal 2026 ended November 30, 2025 (Q1:2026) and provided an update on operational progress for the quarter."During the first quarter of fiscal 2026, Lobe meaningfully accelerated its research and development activities, with R&D expenditures increasing to just under $1 million as we advanced our core programs through Cynaptec Pharmaceuticals, Inc.," said Dr. Fred Sancilio, CEO of Lobe Sciences Ltd. "This progress reflects our transformative approach to drug development of next-generation serotonergic agents, combining our advanced pharmaceutical development expertise, focused subsidiary-level execution with centralized scientific and regulatory core competencies. Importantly, this increased level of activity was achieved alongside improved operating efficiency, underscoring the benefits of our shared services model. We believe this disciplined and scalable approach positions the Company to continue advancing development initiatives while maintaining a strong financial foundation".First Quarter 2026 Financial HighlightsCash totaled $5,991,614 as of November 30, 2025.Short-term investments totaled $1,025,098 as of November 30, 2025.Net working capital totaled $4,047,891 as of November 30, 2025.Research and development expenses totaled $982,087 for the quarter ended November 30, 2025, compared to $7,551 for the same period in the prior year. The increase reflects expenditures related to advancing L-130 (Psilocin Mucate) through preclinical studies and regulatory activities supporting proof-of-concept and investigational new drug filings.Cash flows used in operating activities were $579,006 for the quarter ended November 30, 2025, compared to $243,068 for the same period in the prior year.Net loss was $1,305,827 for the quarter ending November 30, 2025, compared to $800,634 for the same period last year.Operational HighlightsDuring the quarter, Lobe continued to execute on its development strategy, with the majority of research and development expenditures incurred through Cynaptec Pharmaceuticals, Inc., the Company's subsidiary advancing L-130 (Psilocin Mucate). During Q1:2026, Lobe initiated and advanced preclinical, clinical, and regulatory activities, progressing the program in accordance with its development plan.The Company maintained a fiscally conservative approach throughout the quarter, implementing tight controls over the use of cash while increasing development activity. In parallel, Lobe strengthened its development capabilities by adding additional scientific resources to support the advancement of its research and development efforts as programs move toward Phase 1 and Phase 2 clinical activities.Product Development OverviewLobe is advancing two strategic development programs through its subsidiaries:Cynaptec Pharmaceuticals, Inc. (64% owned by Lobe) - L-130 for chronic cluster headache (lead program) and opioid use disorder, with other indications under strategic review.Altemia, Inc. - S-100, an early-stage drug product candidate for sickle cell disease.In addition to these two ongoing programs, the Company continues to evaluate other strategic opportunities consistent with its business strategy.Cynaptec Pharmaceuticals, Inc.: L-130 - A CNS TherapeuticL-130 is a proprietary, orally administered compound engineered as a stabilized derivative of psilocin, the pharmacologically active metabolite of psilocybin. The formulation is designed to improve stability and systemic exposure, with the objective of supporting consistent therapeutic performance. Psilocin has demonstrated potential utility across a range of neurological disorders.L-130 is being developed initially for the treatment of chronic cluster headache, a debilitating neurological condition for which current therapeutic options remain limited. As previously disclosed in the Company's Management's Discussion and Analysis, a Phase 1a clinical study in healthy volunteers, together with a comprehensive body of supporting preclinical studies, has been completed outside of the United States in accordance with applicable regulatory and ethical standards. The Company continues to advance its development and partnering strategy in alignment with guidance received from the U.S. Food and Drug Administration through its Pre-IND interactions and through its regulatory network.Altemia, Inc.: S-100 - Sickle Cell Disease Drug Product CandidateDuring the quarter, Lobe also focused on its sickle cell disease program, S-100, an early-stage therapeutic candidate intended to address core disease mechanisms. S-100 utilizes a proprietary drug delivery approach and consists of a multi-component, polyunsaturated lipid-based formulation, primarily comprising of triglyceride esters of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), together with a patented absorption enhancing blend of excipients.In addition, during the quarter the Company continued limited preliminary commercialization activities related to a proprietary medical food designed to address nutritional deficiencies commonly observed in patients with sickle cell disease. These activities remain focused on evaluating potential pathways for third-party reimbursement specifically in the State of Georgia. There can be no assurance that reimbursement approval will be obtained or that commercialization efforts will be successful. Should reimbursement not be achieved, the Company may pursue alternative strategies or elect to discontinue further commercialization activities.Capital and Potential Value-Creation StrategyDuring the quarter, the Company continued to execute its value creation strategy focused on advancing and realizing the intrinsic value of its existing research and development assets, while selectively evaluating additional opportunities aligned with its business objectives.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE.About Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F)Lobe Sciences Ltd. is a biopharmaceutical company advancing programs in diseases with unmet medical needs. The Company is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals, Inc. and wholly owned subsidiary Altemia, Inc.About Cynaptec Pharmaceuticals, Inc.Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders. Cynaptec's initial development program is focused on the use of its proprietary L-130 (psilocin mucate) compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders. Cynaptec is 64% owned by Lobe.About L-130 (psilocin mucate)L-130 is a novel, patented, oral, stable analog of psilocin, the active metabolite of the prodrugpsilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions. Whereas conventional psilocin is an unstable compound that has been challenging for the industry to develop as a standalone pharmaceutical, L-130 stability and bioavailability profile, and associated safety and efficacy signals, suggest the potential for prescription drug development in a variety of neurological and psychiatric indications.For Further InformationDr. Frederick D. Sancilio
Chief Executive Officer
Lobe Sciences Ltd.
Email:

$LOBEF Lobe Sciences Provides Update For 2023 Milestones

https://finance.yahoo.com/news/lobe-sciences-provides-2023-milestones-120000347.html

$LOBEF
$LOBE

https://m.facebook.com/story.php?story_fbid=pfbid02C76XCRoPZmEQQaCy435x48tDVB2WTEA4DoprweGK9awqPEvzCeViWms8UFJGf6Phl&id=100063495463757&mibextid=qC1gEa

LOBEF
LOBE SCIENCES LTD.
LOBEF (OTCQB) LOBE.CN (CSE)


Summary

Stock Price: $0.0348

Market Cap: $2,668,818

52-week Range: $0.0211 - 0.2686

Avg. Volume: 28,362

(As of January 16, 2023)

Company Description:
Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

Recent News:

- Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130 https://www.otcmarkets.com/stock/LOBEF/news/Lobe-Sciences-Provides-an-Update-to-Clinical-Development-Plans-for-Its-Proprietary-Psilocin-Product-L-130?id=382169
- Lobe Sciences to Present at MONEYSHOW VIRTUAL EXPO November 10, 2022 https://www.otcmarkets.com/stock/LOBEF/news/Lobe-Sciences-to-Present-at-MONEYSHOW-VIRTUAL-EXPO-November-10-2022?id=379346
- Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials https://www.otcmarkets.com/stock/LOBEF/news/Lobe-Sciences-Announces-the-Completion-of-cGMP-Production-of-Clinical-Supplies-For-Upcoming-Clinical-Trials?id=375920

I got 8300 shares, hoping for big big news any day now

(CSE: $LOBE) (OTCQB: $LOBED)- Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023
#BIO #SCIENCE #BioTechnology #investors #otc #nasdaq #wallstreet #psychedelic #research #PHARMA

https://www.otcmarkets.com/stock/LOBED/news/Lobe-Sciences-Ltd-Announces-Regulatory-and-Clinical-Development-Plans-For-2022-and-Early-2023?id=364009

$GTSIF / $LOBED - Lobe Sciences Announces Roadmap for Remainder of 2022 and Early 2023
https://www.otcmarkets.com/stock/LOBED/news/Lobe-Sciences-Announces-Roadmap-for-Remainder-of-2022-and-Early-2023?id=361160

CSE: $GTSIF ($LOBED:OTCQB) Lobe Sciences Ltd. and Clearway Global LLC Enter into a Development Agreement to Manage Lobe Sciences Ltd.'s Global Regulatory and Development Strategy and its Implementation

#BIO #SCIENCE #BioTechnology #investors #otc #nasdaq #wallstreet #psychedelic #research #PHARMA

https://www.otcmarkets.com/stock/LOBED/news/Lobe-Sciences-Ltd-and-Clearway-Global-LLC-Enter-into-a-Development-Agreement-to-Manage-Lobe-Sciences-Ltds-Global-Regulat?id=361962

$GTSIF / $LOBED - Lobe Sciences plans to advance to Phase 1 PTSD study in second half of 2022 with psilocybin and NAC #BIO #SCIENCE #BioTechnology #investors #otc #nasdaq #wallstreet #psychedelic #research

Lobe Sciences plans to advance to Phase 1 PTSD study in second half of 2022 with psilocybin and NAC - YouTube

$GTSIF:CSE $LOBE $LOBED @lobesciences reports its roadmap for the remainder of 2022 and into 2023.

Philip Young CEO and Director said, "I am happy to report that we have made significant progress since our last update in Q3 last year."

#psychedelics #MentalHealth https://www.newsfilecorp.com/release/127677/Lobe-Sciences-Announces-Roadmap-for-Remainder-of-2022-and-Early-2023

LOBEF: one for 6 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Effective Nov. 15,2021 GTSIF will change to LOBEF:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

LD Micro Presentation:

https://me21.mysequire.com/recording?session_id=4d501921-13a9-49e2-bf6a-ec2969c5c4ef

What a day so far

Looks like GTSIF is making a move up. They have solid research and are a potential winner.

Doji

Hopefully that will drive some interest here.

Lobe Sciences(GTSIF) to present themselves at LD Micro Invitational XI

On the Sequire Virtual Events platform, 2021 LD Micro Invitational will be hosted from Tuesday 8 to Thursday 10 June 2021.
The meeting will be place every day from 7:00 PM PT-15:00 PM PT - 6:00 PM ET.
Around 180 firms are planned to attend this three-day virtual investment conference with a total of 25 minutes apiece, together with a number of important events. An extraordinary one-time event will also be held on the first day of the conference: the LD Micro Hall of Fame.

Seems to be a solid company share structure and financials wise. Anything in the near future to get more attention?

Lobe Sciences(GTSIF) announces the acquisition of Vitamind Wellness Product Line.

"We hope to expand on this product line with more research aimed at increasing brain function and treating mild traumatic brain illness. We look forward to creating other goods in the near future, as well as securing production facilities and expanding the brand," said Philip Young, CEO and Director of Lobe Sciences.

Today, I am bringing you Lobe Sciences (GTSIF) because we could be in the beginning stages of the “Shroom Boom!”... Just like how we nailed CODX during the Diagnostics Boom, when I first alerted it on July 2, 2019 at $.85/share and continued coverage all the way to its high of $30.99/share on August 3rd, 2020.
For +3,545.88% in Potential Gains.

The above is from an email this morning from https://www.otctipreporter.com/

Lobe Sciences Ltd. and HAVN Life Sciences Inc. in partnership

Philip Young, CEO, and Director of Lobe stated We are very happy to enter into this agreement with a partner HAVN Life Sciences Inc that is harmoniously dedicated to the development of innovative products. Our agreement also reflects Lobe’s continued ability to collaborate and execute on transactions providing value to shareholders.

https://yhoo.it/3fDUbpS

GTSIF coverage from otctipreporter.com/ Past coverage FDIT AIKI CODX date they started covering.
FDIT
June 2020
AIKI
Covered approx. Jan 26
CODX
covered Jan. 2020

BREAKOUT ALERT

Company: Lobe Sciences Ltd.

Symbol: (GTSIF)

Range: $.08 -.09

Catalyst: New Legislation to open doors for “Shroom Boom”

May 30, 2021

From the desk of OTCTipReporter https://www.otctipreporter.com/

GTSIF- Lobe Sciences secures Vitamind production and supply deal

Lobe Sciences (GTSIF) signs a manufacturing and supply deal with HAVN Life Sciences, a biotechnology business seeking standardized extraction of psychoactive substances and the development of natural healthcare products, on May 14, 2021.

https://seekingalpha.com/news/3698186-lobe-sciences-bags-production-and-supply-agreement-for-vitamind

Could we be seeing a rebound here to where we were in mid February?

Nice Find!

Lobe Sciences Invites You to Join Us at the Q2 Virtual Investor Summit

2021-05-12 05:04 PT - News Release


Vancouver, British Columbia--(Newsfile Corp. - May 12, 2021) - Lobe Sciences (CSE: LOBE) today announced that Philip Young, CEO and Director, will be attending the Q2 Virtual Investor Summit.

Event Q2 Investor Summit
Date May 17-18th, 2021
Presentation May 18th at 10:15 AM ET
Location https://zoom.us/webinar/register/WN_9O2Bo2GAS-Ks6W5cFJKFWQ


About Lobe Sciences

Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information:

Lobe Sciences
Philip Young CEO & Director
(949) 505-5623
info@lobesciences.com

About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q2 Investor Summit will take place virtually, featuring 80+ companies and over 300 institutional and retail investors.

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com.

Contact:

Sasha Murray at sasha@investorsummitgroup.com

Anyone know when we should expect an update on the research with U of Miami?

LOBE Presenting At Virtual Investor Conference Friday!

Lobe Sciences Invites You to Join Us at the Q2 Virtual Investor Summit

2021-05-12 05:04 PT - News Release


Vancouver, British Columbia--(Newsfile Corp. - May 12, 2021) - Lobe Sciences (CSE: LOBE) today announced that Philip Young, CEO and Director, will be attending the Q2 Virtual Investor Summit.

Event Q2 Investor Summit
Date May 17-18th, 2021
Presentation May 18th at 10:15 AM ET
Location Register Here


About Lobe Sciences

Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information:

Lobe Sciences
Philip Young CEO & Director
(949) 505-5623
info@lobesciences.com

Looks Pretty Legit. Most In This Space Are Just Planning To Sell Dried Mushrooms But LOBE Is Doing Real Research At U of Miami. Looks like a good time to finally get a position!

good slow, steady climb here. Looking good with no news and no attention.

News
https://finance.yahoo.com/news/lobe-sciences-signs-definitive-agreement-134000407.html

the monster has been released from her chains

adding another 10K at .16. Hoping this is a bit of a dip for today and then back to climbing.

Testing resistance at .17 a couple times already today.

Continuing a good run. This one is looking interesting.

Thanks BillionsMatter, I started some DD last night and got in this morning at open for .13, bought some more at .14.

MAJOR COVERAGE OUT FROM OTC TIP REPORTER: #1 New Blockbuster Biotech Stock

Lobe Sciences Ltd. (GTSIF) Set to EXPLODE

As Wall Street & Silicon Valley Invest Heavily Into This

Explosive Space (This is like Cannabis in 2015-2016)

You Need to Get Ready for the “Shroom Boom” by

Pulling Up Lobe Sciences (GTSIF) Right Now

(GTSIF) Has a History of Making +1,067.72% Runs,

You Would Hate to Miss Out On Their Next One.

Dear Fellow Trader,

Immediately Turn Your Attention to Lobe Sciences (GTSIF)

Investor interest in this space is sending psychedelic stocks soaring to new heights. Do not Wait on Lobe Sciences (GTSIF).

If you are a new member, we’d like to “Welcome You” and start you off with our next potential breakout gainer Lobe Sciences (GTSIF).

For our existing members, I’d like to “Thank You” and cong·ratulate you on a string of massive winners… Starting with yesterday’s alert on (SPONF), which opened at .017 and ran to .028 on massive volume showing our members a potential intra-day gain of +64.70% in just a few hours.

Then today SPONF ran to a high of .04 running up +135.29% from yesterdays alert price of .017 and it ran up +354.54% from my alert at .0088 on Jan.19th.

And while we are at it, take a look at these recent gainers below...

RECENT GAINERS FROM 2021

February 8th, QSAM alerted at $.85 ran to $1.09 on February 9th for Potential Gains of +28.24% (Not bad for one day)

January 19th, SPONF alerted at $.0088 ran to $.0318 on January 26th for Potential Gains of +261.36%

January 12th, GWHP alerted at $.49 ran to $2.17 on January 21st for Potential Gains of +342.86%

January 6th, AIKI alerted at ($.84 pre-market) ran to ($2.65 pre-market) on Feb. 16th for Potential Gains of +215.47%

February 1st, FDCT alerted at $.47 ran to $.945 on February 10th for Potential Gains of +100%

Keep Reading So You Can See Why I Am So Excited About

Lobe Sciences (GTSIF) And It’s Heart-Pounding Potential For Your Portfolio

Our next alert brings us all the way to Vancouver, British Columbia where “The Prairies” have been a hub for psychedelic research since the 1950's.

Lobe Sciences (GTSIF) is a Vancouver-based life sciences company focused on the development of psychedelic medicines. They are focused on the research and the clinical development of psilocybin-based therapeutics for the treatment of mild Traumatic Brain Injuries (mTBIs) and Post-Traumatic Stress Disorder (PTSD).

Lobe is also working towards building devices and delivery mechanisms for the efficient application of medications.

Lobe Sciences owns acquired brands, intellectual property with respect to the psychedelics business whereas it generates its regular stream of cash flows through leasing office and production premises to cannabis processors and retailers.

The company has a highly experienced team and strong partnerships with universities that are helping it build on its research. We will discuss Lobe Science’s management team later in this report, but keep reading to see why we are so excited about Lobe Sciences (GTSIF)

Lobe Sciences (GTSIF) Core Offerings:

Psychedelics are known to have a strong application in the mental health space, particularly in PTSD as they have the ability to alter the perception and the mood of an individual and impact various cognitive processes.

Research has shown that many of these are safe to consume from a physiological standpoint and do not lead to dependence or addiction. Lobe Sciences is working towards building therapeutics that can make the optimum use of such psychedelics to help improve the mental health of patients suffering from PTSD of mTBIs.

The company has launched a preclinical research study using psilocybin (commonly known as Magic Mushrooms) and N-Acetylcysteine (“NAC”) for the treatment of mTBIs including various forms of concussion as well as PTSD.

NAC is basically a dietary supplement derived from the amino acid L-cysteine that has strong applications as an antioxidant for reduction of DNA damage, as an antidote for acetaminophen overdose, and for its liver-protective properties and to support a healthy functioning of the immune system.

Apart from combining NAC with psilocybin, Lobe is also working on patents associated with the combination of MDMA (commonly known as Ecstasy) and NAC for achieving a similar purpose.

Preclinical studies with respect to these combinations are being conducted by Lobe along with the scientists at University of Miami’s Miller School of Medicine under the leadership of Michael E. Hoffer, MD professor of otolaryngology and neurological surgery. More on this later when we discuss recent news.

Delivery Devices As A Product:

The second major aspect of Lobe’s research is associated with the delivery devices. The company is engaged in developing a nasal mist transducer device that can directly deliver the relevant medication to the olfactory bulb. It has the possibility of being combined with a virtual reality headset to have an augmented effect on the mentally ill individual.

Lobe is building this technology with engineering design and developmental support from Visionworks Engineering. The company will look to file a patent for this technology as well and it has a much faster timeline of development and should be ready over the coming 6 months. It is expected to have a strong application in this field.

VisionWorks Engineering provides medical device engineering services that meet US FDA and international regulatory bodies and standards. They work with medical device start-ups and industry leaders alike in the development of new medical devices.

Medical device companies can leverage VisionWorks Engineering expertise in bringing new medical devices to the market at any stage in the product development process. VisionWorks Engineering has helped their clients as they go through concept development, detail design, prototyping, testing, clinical trials, premarket approval, and final FDA approval for their new medical device products.

VisionWorks Engineering's medical device engineering experience covers a wide range of products. A few examples of the medical products they have helped to develop and bring to market include:

Portable HIV test system
Battery operated centrifuge
Disposable gauze applicator
Ophthalmic surgical system components
And now Lobe Sciences (GTSIF) and VisionWorks Engineering are working together on their nasal mist transducer device and will look to file a patent for this technology.

You see, what you need to realize here, is that Lobe Sciences (GTSIF) is not only developing the drugs using psilocybin, but they are also developing (and ideally patenting) the delivery methods as well.

Wall Street & Silicon Valley Leaders Are Rushing

to Support Psychedelic Medicine

As psilocybin boldly merges into modern pharmacopeia, the emerging field of psychedelic medicine continues forward amidst this electrifying renaissance. Pioneers such as MAPS, Usona Institute and Compass Pathways have been awarded the coveted “breakthrough status” for their psilocybin-based therapies by the US Food & Drug Administration. This designation marked a historic moment for the overall psychedelic revolution and has caught the attention of various notable investors from Wall Street and Silicon Valley.

Peter Thiel, the notable venture capitalist backer of Compass Pathways, is the co-founder of PayPal and one of Facebook’s first major investors. He is also the chairman of Palantir Technologies, which as of today has a market cap of over $54B dollars.

Thiel’s combined investments in Palantir and Compass Pathways highlights the significant shift in attention towards psychedelics from big players in Wall Street and Silicon Valley.

Looking at Thiel’s track record along with the significant attention towards psychedelics from big players in Wall Street and Silicon Valley, Thiel may be onto something by investing in the psilocybin sector!

UFC looks into Johns Hopkins study on psychedelic drugs as potential therapy for fighters

The UFC is looking to get involved with research into psychedelic drugs as a therapy for fighters' brain health.

The promotion has been in contact with Johns Hopkins University about its psychedelic studies with an eye toward seeing if the drugs can be helpful for fighters dealing with brain issues, UFC president Dana White told MMA Junkie last month.

"We're diving into that," White said.

UFC senior vice president of health and performance Jeff Novitzky told ESPN that the interest came from a segment from HBO's "Real Sports" last month. Novitzky said White gave him a "directive" to look more into psychedelic research and he has been in contact with Johns Hopkins over the past few weeks.

The UFC has been a key funder of a professional athlete brain study being conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health, contributing another $1Mil last Month . Novitzky said the promotion could look to be a benefactor toward a psychedelic study with the added possibility of recruiting current or former UFC fighters to be part of the research.

"Dana said, 'Hey, find out what this is about,'" Novitzky said. "To see if it does help with some traumatic brain injury, addiction, mental-health problems. We want to be on board and we want to be first."

Johns Hopkins is the nation's leader in research on the therapeutic effects of psychedelics such as psilocybin (mushrooms) and LSD. The Johns Hopkins Center for Psychedelic & Consciousness Research gained regulatory approval from the U.S. government in 2000 and has produced more than 60 pieces of peer-reviewed research.

Currently, psilocybin and other psychedelics are classified by the U.S. government as illegal Schedule I drugs, defined as drugs with a high potential for abuse or drugs that have no medical uses.

However, views on psychedelics are changing.

Lega·lization of psychedelics for use in medicine is gaining momentum across the United States.

Advances in Lega·lization:

Lega·lization of psychedelics for use in medicine is gaining momentum across the United States. San Francisco, California, and Oakland and Santa Cruz, California, have decriminalized the use of psilocybin, the psychedelic molecule found in various mushrooms, while movements for lega·lization are gaining ground in Oregon and Iowa, among others. Decriminalize California recently teamed up with the Beckley Foundation to replicate Oakland’s success of decriminalization throughout the state of California.

An increasing number of researchers are turning their attention toward the study of psilocybin as a means to treat otherwise untreatable illnesses. The molecule’s ability to provide landmark treatment options for depression, post-traumatic stress disorder (PTSD), migraines and addiction is gaining widespread acceptance among medical professionals, unicorn investors and accredited institutions.

Potential Applications:

Historical data and new scientific studies suggest therapeutic benefits of psychedelics in many areas, including drug addiction, alcoholism, depression, migraines, smoking cessation and post-traumatic stress disorder (PTSD).

The market potential in these areas are significant. To reference just one of the above conditions, the mental health arena has been frequently neglected over the last 30 years, though new research is beginning to further reinforce that psychedelic compounds have the potential to produce more effective treatments than what is currently available.

According to the World Health Organization, 25% of the world’s populous will be afflicted by mental health and/or neurological disorders. Presently, approximately 450Mil people currently suffer from such conditions, placing mental disorders among the leading causes of ill-health, productive loss and disability worldwide.

Additionally, PTSD affects approximately 2.2% of the U.S. population; 7.7mil people will have PTSD at some point in their lives. Recent published studies have demonstrated the safety and efficacy of certain psychedelics when administered in a medically supervised and monitored approach.

Lobe Sciences (GTSIF) is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

This could prove to be a major catalyst in propelling Lobe Sciences into becoming a key player in this space. Especially with any type of Patent or FDA Approval in the future.

Lobe Sciences (GTSIF) Gets “INCREDIBLE”

12 BUY RATINGS

Wall Streets leading provider of market data to the global financial, media, and commodity industries Barchart.com just Triggered an "INCREDIBLE" 12 BUY SIGNALS on Lobe Sciences (GTSIF) across the Short-Term Indicators, Medium-Term Indicators and even the Long-Term Indicators.


What You need to keep in mind is that BarChart just triggered these 12 BUY SIGNALS after (GTSIF) has already run +1,067.72% within the past year. You Would Hate to Miss Out On Their Next One.

This would be like turning $5,000 into $53,350… And I don’t know anyone who would want to miss out on that.

Lobe Sciences (GTSIF) Has a Very Accomplished Managed Team

That is Ready to Advance the Company and Drive Shareholder Value.

MANAGEMENT TEAM:

PHILLIP J. YOUNG - CEO & Director

Mr. Young is an analytical and results driven life sciences executive who has successfully managed public and private companies through product development, international growth, commercialization and M&A transactions. He has served as a Director and Chief Executive Officer for public companies for the past 20 years where he has created significant shareholder value, built integrated scientific, manufacturing, and commercial operations, directed successful M&A transactions and was responsible for generating more than $900M through acquisitions and equity financings. Mr. Young started his management career in the biopharmaceutical industry at Genentech Inc. where he was responsible for their cardiovascular and endocrine product launches sales and marketing.

BRIAN ZASITKO - Chief Financial Officer

Brian has over 13 years of experience across a variety of private and public sector companies in the cannabis, agriculture, manufacturing, and utility industries. He has extensive experience in financial reporting and corporate governance, as well as in the capital markets. Previously, Brian was a manager at Ernst & Young LLP, where he obtained his CPA, CA designation.



MAGHSOUD DARIANI - Chief Science Officer



Concurrent to leading science and technology efforts at LOBE, Maghsoud is also President and CEO of Semorex Inc. – a privately held company focused on the discovery and development of novel therapeutics for cancer. Prior to joining Semorex, Dariani was President of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage, then successfully negotiated the sale of the company in February 2003. Prior to Focus, Maghsoud was Vice President of the chiral pharmaceutical business unit at Celgene Corporation. During his twelve years at Celgene, he was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names.



Dr. MARK A. GEYER PHD. - Science Advisor



Dr. Geyer is Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD) and directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center. Since receiving his doctorate in Psychology in 1972, he has focused on basic research addressing the behavioral and neurobiological effects of psychedelics and other psychoactive drugs. Dr. Geyer is respected internationally for his research. He has published over 470 peer-reviewed papers, including many addressing the mechanisms subserving the effects of psychostimulants, psychedelics, and entactogens. Dr. Geyer’s broad experience as a researcher, grant reviewer, journal editor, and teacher lends invaluable scientific and professional expertise to our Company.



JONATHAN GILBERT - Executive Chairman



Most recently, Jonathan was the founder and CEO at Tassili LifeSciences, Corp., a biotech firm conducting research utilizing Psilocybin. Tassili was successfully acquired by a public company in March of 2020. He was also the founder and CEO of Scythian Biosciences, Inc. from December of 2014 through May of 2018. Scythian was a publicly traded research and development company in Canada focusing on the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination, as well as strategic investments and partnerships across cultivation, distribution, and retail of legal Cannabis. Prior to founding Scythian Biosciences, from January 2013 to December 2014, Gilbert was Marketing Officer for Commonwealth Oppo·rtunity Capital, GP, a hedge fund based in Greenwich, Connecticut. From October of 1995 until December of 2012, Jonathan was the owner and operator of Gilbert Capital Management, Corp., a full service private wealth management firm



LEIGHTON BOCKING – Director



Leighton has been working in the capital markets for over15 years. His primary role has been as an independent corporate development consultant in addition to holding various directorship positions. Leighton has been particularly focused on financing and structuring companies. An active investor, he started in the industry at Canaccord before moving to the public company side of the business.



MICHAEL PETTER - Director



Michael is an accomplished leader and entrepreneur in the psychedelics and cannabis industry, co-founding and acting as a director of several companies that successfully completed M&A transactions. He holds a Bachelors in Computer Science from London University, is a Chartered Engineer and private pilot. Since January 2009, he has been the Managing Director of Eyvo eProcurement Solutions, a US-based private company that is a leading eProcurement provider in the SaaS space. He also runs a business mentoring program that assists businesses and individuals with change management. Mike was co-founder and director of Eleusian Biosciences Corp., which the Company acquired in July 2020. He also co-founded and was a director of Tassili Life Sciences Corp. which was acquired by CSE-listed Champignon Brands Inc. in March 2020. Mr. Petter has independent board experience being chairman of a compensation committee and as a member of an audit committee. His executive advisory skills focus on providing guidance on strategy, operations, finance, and logistics.

5 Potential Catalyst That Could Send Shares of

Lobe Sciences (GTSIF) Soaring This Week.

Potential Catalyst #1 Lobe Sciences Ltd.(GTSIF): Recently appointed Chief Medical Officer, Maghsoud Dariani, is not only one of the most sought-after experts in psychedelic medicine, but—as president of Focus Pharmaceuticals—he has already managed the development and FDA approval of similar products. As you can imagine, having someone on board who has already been through the entire FDA cycle and come out the other end successfully is a huge advantage for Lobe (CSE:LOBE | OTC:GTSIF)

Potential Catalyst #2 Lobe Sciences Ltd.(GTSIF): has been active with acquisitions Thanks to its acquisition of Eleusian Biosciences in July 2020, Lobe Sciences already has five provisional patent applications for unique combinations of psychedelics and medical devices to be used in the treatment of PTSD and mTBI.

Potential Catalyst #3 Lobe Sciences Ltd.(GTSIF): Wall Street & Silicon Valley Invest Heavily Into This Explosive Space with notable venture capitalist Peter Thiel even getting into the mix with his investment in Compass Pathways. So is Mr. Wonderful, Kevin O'Leary as he recently invested into a psychedelic company citing the potential of its drugs to address problems like depression, alcoholism, and opioid addiction, issues that haven’t seen medical innovations in almost three decades.

Potential Catalyst #4 Lobe Sciences Ltd.(GTSIF): Wall Streets leading provider of market data to the global financial, media, and commodity industries Barchart.com just Triggered an "INCREDIBLE" 12 BUY SIGNALS across the Short-Term Indicators, Medium-Term Indicators and even the Long-Term Indicators.

Potential Catalyst #5 Lobe Sciences Ltd.(GTSIF): Has a history of making BIG MOVES. From last May's low price of $.0158, the stock has run as much as +1,067.72% in a few short months when it hit a high of $.1845. (GTSIF) has pretty pulled back a little bit in the beginning of February when it's RSI dropped all the way down below .34 which has since reversed and is heading in the right direction would be signaling that another massive breakout is coming.

This could be the chance to take advantage of a company in a practically untapped market which is exhibiting strong growth potential, extreme diversity, and a highly-favorable technical setup!

LOBE SCIENCES (CSE:LOBE | OTC:GTSIF) just pulled back to an Attractive Price and Could be setting up for its Next Potential Major Breakout to the Upside, if their RSI cross-over .70 there is No-Telling what could happen.

You need to be ready “First Thing” Thursday morning.

Do not wait on Lobe Sciences (GTSIF). This stock trades on the US and Canadian Markets, so there could be more investors or traders who will be looking to gobble up shares as soon as the market opens tomorrow morning.

You need to have Lobe Sciences (GTSIF) up on your screen (First Thing) Thursday morning! Do not waste time.

Do not miss out on LOBE SCIENCES.

Sincerely,

Editor In Chief, OTCtipReporter Team